SWX:NOVNPharmaceuticals
Novartis (SWX:NOVN) FDA Approval Puts Pluvicto Value Story Back In Focus
Novartis (SWX:NOVN) is back in focus after the US FDA approved Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, materially widening the therapy’s eligible patient pool.
See our latest analysis for Novartis.
Against this backdrop, Novartis shares trade at CHF125.98, with a 90 day share price return of 10.8% and a year to date share price return of 16.11%. The 1 year total shareholder return of 38.01% points to...